Hims & Hers Health (NYSE:HIMS) Shares Gap Up – What’s Next?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) gapped up prior to trading on Wednesday . The stock had previously closed at $26.69, but opened at $29.12. Hims & Hers Health shares last traded at $29.91, with a volume of 4,641,419 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on HIMS shares. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Truist Financial increased their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. TD Cowen upped their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 8th. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Finally, Bank of America raised their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus target price of $21.21.

Hims & Hers Health Stock Up 5.6 %

The firm has a market capitalization of $6.05 billion, a PE ratio of 67.77 and a beta of 1.06. The business’s fifty day moving average price is $19.25 and its 200 day moving average price is $18.70.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. The business’s revenue was up 77.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Oluyemi Okupe sold 269,739 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the sale, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 854,547 shares of company stock worth $15,987,230 in the last 90 days. Company insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. Swiss National Bank lifted its holdings in Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after acquiring an additional 2,000 shares during the period. Sei Investments Co. raised its position in Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after purchasing an additional 37,890 shares during the last quarter. Headlands Technologies LLC bought a new position in Hims & Hers Health during the 1st quarter valued at approximately $228,000. Avantax Advisory Services Inc. bought a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $156,000. Finally, ProShare Advisors LLC raised its position in shares of Hims & Hers Health by 10.0% in the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock worth $344,000 after acquiring an additional 2,023 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.